SNORA17A: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORA17A

NCBI ID: G677804

SNORA17A

Other Name(s): small nucleolar RNA, H/ACA box 17A | ACA17 | Small nucleolar RNA, H/ACA box 17A | SNORA17

SNORA17A: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is H/ACA box 17A (SNORA17A), which is expressed in various tissues and cell types and is involved in the regulation of various cellular processes.

SNORA17A has been identified as a potential drug target and biomarker due to its unique structure and function. This article will provide an overview of SNORA17A, including its structure, function, and potential as a drug target or biomarker.

Structure and Function

SNORA17A is a 24.8-nt RNA molecule that contains a unique H/ACA box 17A. The H/ACA box is a conserved sequence that is present in various snRNAs and is known for its role in the regulation of gene expression. The H/ACA box is a cis-regulatory element that can interact with various transcription factors to regulate gene expression.

SNORA17A has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and DNA replication. It has been shown to interact with various transcription factors, including Ku70 and Snail2, which are known to play a role in the regulation of cell growth and apoptosis.

SNORA17A has also been shown to be involved in the regulation of DNA replication. In eukaryotic cells, DNA replication is a critical process that is essential for the maintenance of genetic diversity. SNORA17A has been shown to interact with the protein DNAA1, which is involved in the regulation of DNA replication.

Potential as a Drug Target

SNORA17A has been identified as a potential drug target due to its unique structure and function. The H/ACA box 17A is a cis-regulatory element that can interact with various transcription factors to regulate gene expression, making it an attractive target for small molecules.

SNORA17A has also been shown to play a role in the regulation of cell growth and apoptosis, which are important processes that are often targeted by drugs. By targeting SNORA17A, drugs can potentially inhibit the regulation of these processes and enhance cellular stress response.

SNORA17A has also been shown to be involved in the regulation of DNA replication, which is another process that is often targeted by drugs. By targeting SNORA17A, drugs can potentially inhibit the regulation of DNA replication and enhance the risk of DNA damage.

Potential as a Biomarker

SNORA17A has also been shown to be expressed in various tissues and cell types, which makes it an attractive biomarker for the detection of diseases. The regulation of SNORA17A expression is known to be involved in the development and progression of various diseases, including cancer.

SNORA17A has been shown to play a role in the regulation of cell growth, apoptosis, and DNA replication, which are important processes that are often involved in the development and progression of cancer. By targeting SNORA17A, drugs can potentially inhibit the regulation of these processes and enhance the risk of cancer progression.

Conclusion

SNORA17A is a unique small nucleolar RNA molecule that has been shown to play a role in the regulation of various cellular processes. Its H/ACA box 17A is a cis-regulatory element that can interact with various transcription factors to regulate gene expression, making it an attractive target for small molecules. SNORA17A has also been shown to play

Protein Name: Small Nucleolar RNA, H/ACA Box 17A

The "SNORA17A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA17A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets